Does treatment of newly diagnosed idiopathic thrombocytopenic purpura reduce morbidity?
- Iris Treutiger1,
- Jukka Rajantie2,
- Bernward Zeller3,
- Jan-Inge Henter4,
- Göran Elinder1,
- Steen Rosthøj5,
- for the NOPHO ITP Study Group
- 1Sachs’ Children’s Hospital, Stockholm, Sweden
- 2Paediatric Department, Jorvi Hospital, University of Helsinki, Finland
- 3Paediatric Department, Rikshospitalet, Oslo, Norway
- 4Childhood Cancer Research Unit, Department of Woman and Child Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
- 5Paediatric Department, Aalborg Hospital, Denmark
- Correspondence to:
Dr S Rosthøj
Paediatric Department, Aalborg Hospital, Reberbansgade, 9100 Aalborg, Denmark;
- Accepted 13 April 2007
- Published Online First 25 April 2007
Aim: To explore whether early treatment of children with idiopathic thrombocytopenic purpura (ITP) with immunoglobulin and/or corticosteroids reduces subsequent morbidity.
Methods: Centres participating in a Nordic ITP study were divided according to whether they had treated more than 2/3, from 1/3 to 2/3, or less than 1/3 children within 14 days of diagnosis. The course of disease from 15 days to 6 months after diagnosis was compared for children managed at the three centre categories. The comparison was restricted to children in whom at least one platelet count <20×109/l was measured, numbering 156, 143 and 84 in the three different categories, respectively.
Results: The three groups of children were clinically similar but were managed with initial treatment rates of 89%, 57% and 14%, respectively. By day 15, the platelet count had stabilised to >20×109/l in 67%, 67% and 52% (p<0.05) and to >150×109/l in 38%, 29% and 29% (p<0.20). At 1 month after diagnosis there was no difference in recovery rates. Chronic ITP developed in 27%, 22% and 25% in the three groups. During follow-up, one or more disease-related events occurred in 23%, 22% and 19%, with no difference in the average numbers of episodes with mucosal bleeding. Treatment courses were administered to 19%, 13% and 11%, respectively.
Conclusion: Active treatment policies accelerated platelet recovery in children with short-lasting ITP but did not avert the development of chronic ITP and did not cause a reduction in morbidity during follow-up.
Published Online First 25 April 2007
Competing interests: None.